Welcure Drugs & Pharmaceuticals Share Price Today

Welcure Drugs Q4FY26 Results: Net loss widens to ₹5,003.73 lakh

Welcure Drugs reported a Q4FY26 net loss of ₹5,003.73 lakh versus a profit of ₹254.09 lakh in Q4FY25. Full-year FY26 net loss stood at ₹567.08 lakh, reversing from a net profit of ₹217.01 lakh in FY25. Revenue from operations rose to ₹38,952.44 lakh in FY26 from ₹2,455.00 lakh in FY25. Auditors flagged inability to verify inventory of ₹1,43,52.36 lakh and unconfirmed advances of ₹15,126.13 lakh. Trade receivables surged to ₹21,333.94 lakh, signaling potential collection pressures despite revenue growth.

Welcure Drugs accepts resignation of Company Secretary Palak Jain

Welcure Drugs & Pharmaceuticals Limited accepted the resignation of Ms. Palak Jain as Company Secretary, Compliance Officer, and key managerial personnel effective June 19, 2026. The resignation, attributed to personal reasons and professional commitments, was acknowledged by the Board. The regulatory disclosure was signed by Managing Director & CFO Chintan Didawala Ganpat.

Welcure Drugs reports net loss of ₹549.01 crore in FY26

Welcure Drugs and Pharmaceuticals Limited reported a net loss of ₹549.01 crore for the financial year ended March 31, 2026, compared to a net profit of ₹217.01 lakh in the previous year. Total revenue from operations for the year stood at ₹2,645.99 lakh. The company's equity share capital increased to ₹12,359.40 lakh during the period.

Welcure Drugs board meets May 29 to approve FY26 results

Welcure Drugs & Pharmaceuticals announced a board meeting on May 29, 2026, to approve audited financial results for the year ended March 31, 2026. The agenda includes reviewing the statutory audit report and finalizing the balance sheet and cash flow statement. The company will file the announcement in XBRL format as per SEBI regulations.

Welcure Drugs & Pharmaceuticals Submits SEBI Compliance Certificate for Q4 FY26

Welcure Drugs & Pharmaceuticals Limited submitted its confirmation certificate under SEBI Regulation 74(5) for Q4 FY26 and annual year ended March 31, 2026. The certificate, issued by Registrar and Transfer Agent Skyline Financial Services Pvt Ltd, confirms no physical share certificates were received for dematerialization during the specified period. The filing was submitted to BSE on April 3, 2026, demonstrating the company's compliance with SEBI depositories regulations.

Welcure Drugs & Pharmaceuticals Reports Q3FY26 Financial Results with Net Profit of ₹106.67 Lakhs

Welcure Drugs & Pharmaceuticals Limited reported Q3FY26 net profit of ₹106.67 lakhs on total income of ₹146.43 lakhs, with significant operational changes from previous quarters. The nine-month performance showed substantial growth with net profit of ₹4340.27 lakhs compared to ₹95.56 lakhs in the corresponding previous period. The company's paid-up equity capital increased to ₹12359.40 lakhs, indicating major capital restructuring during the quarter.